Items tagged with Treatment
WHO position statement on innovative clinical trial designs for development of new TB treatments (post)
The World Health Organization (WHO) is publishing a position statement on Innovative Clinical Trial Designs for Development of New TB Treatments. This document aims to support TB regimen development by highlighting key clinical trial characteristics to help advance novel therapies. It summarises key innovations in TB clinical trial designs, ranging from pharmacokinetic-pharmacodynamic (PK-PD) modelling and new advances in biomarker development to the value of novel clinical trial design methodologies and post-licensure observational studies.
CHMP grants positive opinion for Otsuka’s child-friendly 25 mg dispersible tablet formulation of Deltyba (post)
CHMP grants positive opinion in the European Union for Otsuka’s child-friendly 25 mg dispersible tablet formulation of Deltyba® (delamanid) for the paediatric population weighing at least 10 kg with pulmonary multidrug-resistant TB
Episode 4 of WGND podcast now available online (post)
Episode 4 of the podcast series, The Dose, by the Stop TB Partnership's Working Group on New TB Drugs (WGND) is now available online. Shobha Shukla speaks with TB regimen development experts Dr. Debra Hanna and Dr. Robert Bates on the topic of the PAN-TB collaboration and novel regimen development.
TB Alliance: Community engagement virtual forum (post)
On 12 August 2021, TB Alliance will host a public webinar for community stakeholders to share details of the recently announced results from the ZeNix Phase 3 clinical trial. The trial revealed that the 6-month BPaL treatment regimen (bedaquiline, pretomanid and linezolid) remains effective against highly drug-resistant strains of TB with either reduced dosage or duration of the linezolid component of the regimen. Simultaneously, with the maintenance of efficacy, there was a decrease in linezolid associated side effects.
Publication: Results of the acceptability and feasibility study of the BPaL regimen (post)
TB Alliance and KNCV Tuberculosis Foundation published a study in BMC Public Health, focused on collecting stakeholder views (in Nigeria, Indonesia, and Kyrgyzstan) regarding the acceptability, feasibility, and likelihood of stakeholders implementing the BPaL regimen. BPal is a three-drug, 6-month, all-oral regimen composed of bedaquiline, pretomanid and linezolid for the treatment of highly drug-resistant forms of TB.
Dashboard: Access to the BPaL regimen (post)
TB Alliance launched a webpage to provide information on national-level access to the BPaL regimen - a three-drug, 6-month, all-oral regimen composed of bedaquiline, pretomanid and linezolid for the treatment of highly drug-resistant forms of TB.
Research begins into new digital tools to support patients and healthcare workers through TB treatment (post)
The Hague / Geneva, 4 August 2021 – A large global study which aims to determine if digital adherence technologies (DATs) can provide more patient-friendly approaches to improve tuberculosis (TB) treatment outcomes launches in Ethiopia, Tanzania, South Africa, the Philippines and Ukraine, as part of the ASCENT project.
Otsuka awarded grant for Phase 2 trial combining novel anti-tuberculosis compound OPC-167832 with delamanid and bedaquiline (post)
-- Grant up to $17.8 million will support study of treatment-shortening regimen in drug-sensitive tuberculosis (DS-TB)
-- Study expected to begin in 2022 evaluating safety and efficacy of novel 3-drug combination versus existing 4-drug standard of care
Digital technologies support patients with treatment from a distance, allowing more flexibility in care (post)
As the Unitaid-funded ASCENT project launches the main research phase, investigating the effectiveness of digital adherence technologies and data-driven support interventions on TB treatment completion and success rates, Unitaid asked the researchers leading the study to tell more about their work and its potential impact.
Combined antibiotic dry powder inhaler offers some relief for pulmonary TB (post)
Use of an add-on dry powder inhaler (DPI) containing fixed doses of isoniazid, rifampicin, pyrazinamide, and levofloxacin did not increase sputum conversion in patients receiving standard oral therapy for pulmonary tuberculosis (TB); however, the combined antibiotic DPI did result in greater cough relief, according to study findings published in Pulmonary Pharmacology & Therapeutics.
Page 59 of 106 · Total posts: 0
←First 58 59 60 Last→